Roche to pay $7.1 bn for Telavant Holdings

by

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

Leave A Comment

Your email address will not be published. Required fields are marked *